These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 1693916)
1. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Lass JH; Walter EI; Burris TE; Grossniklaus HE; Roat MI; Skelnik DL; Needham L; Singer M; Medof ME Invest Ophthalmol Vis Sci; 1990 Jun; 31(6):1136-48. PubMed ID: 1693916 [TBL] [Abstract][Full Text] [Related]
2. Decay-accelerating factor (DAF) shares a common carbohydrate determinant with the variant surface glycoprotein (VSG) of the African Trypanosoma brucei. Davitz MA; Gurnett AM; Low MG; Turner MJ; Nussenzweig V J Immunol; 1987 Jan; 138(2):520-3. PubMed ID: 2432127 [TBL] [Abstract][Full Text] [Related]
3. Detection of surfactant proteins A and D in human tear fluid and the human lacrimal system. Bräuer L; Kindler C; Jäger K; Sel S; Nölle B; Pleyer U; Ochs M; Paulsen FP Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):3945-53. PubMed ID: 17724171 [TBL] [Abstract][Full Text] [Related]
4. Phorbol esters increase synthesis of decay-accelerating factor, a phosphatidylinositol-anchored surface protein, in human endothelial cells. Bryant RW; Granzow CA; Siegel MI; Egan RW; Billah MM J Immunol; 1990 Jan; 144(2):593-8. PubMed ID: 1688581 [TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor and hepatocyte growth factor receptor in the lacrimal gland, tears, and cornea. Li Q; Weng J; Mohan RR; Bennett GL; Schwall R; Wang ZF; Tabor K; Kim J; Hargrave S; Cuevas KH; Wilson SE Invest Ophthalmol Vis Sci; 1996 Apr; 37(5):727-39. PubMed ID: 8603858 [TBL] [Abstract][Full Text] [Related]
6. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. Medof ME; Walter EI; Rutgers JL; Knowles DM; Nussenzweig V J Exp Med; 1987 Mar; 165(3):848-64. PubMed ID: 2434600 [TBL] [Abstract][Full Text] [Related]
7. Complement activation induces the expression of decay-accelerating factor on human mesangial cells. Shibata T; Cosio FG; Birmingham DJ J Immunol; 1991 Dec; 147(11):3901-8. PubMed ID: 1719094 [TBL] [Abstract][Full Text] [Related]
8. Detection of the complement (CD21)/Epstein-Barr virus receptor in human lacrimal gland and ocular surface epithelia. Levine J; Pflugfelder SC; Yen M; Crouse CA; Atherton SS Reg Immunol; 1990-1991; 3(4):164-70. PubMed ID: 1966579 [TBL] [Abstract][Full Text] [Related]
9. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice. Gao J; Morgan G; Tieu D; Schwalb TA; Luo JY; Wheeler LA; Stern ME Exp Eye Res; 2004 Apr; 78(4):823-35. PubMed ID: 15037117 [TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage. Venneker GT; van den Hoogen FH; Boerbooms AM; Bos JD; Asghar SS Lab Invest; 1994 Jun; 70(6):830-5. PubMed ID: 7516986 [TBL] [Abstract][Full Text] [Related]
11. Production and localization of Muc4/sialomucin complex and its receptor tyrosine kinase ErbB2 in the rat lacrimal gland. Arango ME; Li P; Komatsu M; Montes C; Carraway CA; Carraway KL Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):2749-56. PubMed ID: 11687512 [TBL] [Abstract][Full Text] [Related]
12. Additional forms of human decay-accelerating factor (DAF). Seya T; Farries T; Nickells M; Atkinson JP J Immunol; 1987 Aug; 139(4):1260-7. PubMed ID: 2440950 [TBL] [Abstract][Full Text] [Related]
13. Human corneal and conjunctival epithelia produce a mucin-like glycoprotein for the apical surface. Watanabe H; Fabricant M; Tisdale AS; Spurr-Michaud SJ; Lindberg K; Gipson IK Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):337-44. PubMed ID: 7531184 [TBL] [Abstract][Full Text] [Related]
15. Surface expression of complement regulatory proteins, decay-accelerating factor (DAF) and CD59, on cultured human endothelial cells. Kunii H; Shichishima T; Saitoh Y; Noji H; Maruyama Y Fukushima J Med Sci; 1998 Dec; 44(2):69-81. PubMed ID: 10091379 [TBL] [Abstract][Full Text] [Related]
16. Localization of the complement membrane attack complex inhibitor (CD59) in human conjunctiva and lacrimal gland. Bardenstein DS; Dietz Y; Lass JH; Medof ME Curr Eye Res; 1994 Dec; 13(12):851-5. PubMed ID: 7536649 [TBL] [Abstract][Full Text] [Related]
17. Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46(MCP), CD55(DAF), and CD59 on human vascular endothelial cells. Moutabarrik A; Nakanishi I; Namiki M; Hara T; Matsumoto M; Ishibashi M; Okuyama A; Zaid D; Seya T Lymphokine Cytokine Res; 1993 Jun; 12(3):167-72. PubMed ID: 7688580 [TBL] [Abstract][Full Text] [Related]
18. Wheat germ agglutinin and other selected lectins increase synthesis of decay-accelerating factor in human endothelial cells. Bryant RW; Granzow CA; Siegel MI; Egan RW; Billah MM J Immunol; 1991 Sep; 147(6):1856-62. PubMed ID: 1716283 [TBL] [Abstract][Full Text] [Related]
19. Decay-accelerating factor on human umbilical vein endothelial cells. Its histamine-induced expression and spontaneous rapid shedding from the cell surface. Tsuji S; Kaji K; Nagasawa S J Immunol; 1994 Feb; 152(3):1404-10. PubMed ID: 7507966 [TBL] [Abstract][Full Text] [Related]
20. Coexistence of autologous antibodies and decay-accelerating factor, an inhibitor of complement, on human renal tumor cells. Terachi T; Stanescu G; Pontes JE; Medof ME; Caulfield MJ Cancer Res; 1991 May; 51(10):2521-3. PubMed ID: 1708695 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]